Transcriptional enhancers in the cell nuclei typically interact with the target promoters over long stretches of chromatin, but the mechanism of this communication remains unknown. Previously we have developed a defined system for quantitative analysis of the rate of distant enhancer-promoter communication (EPC) and have shown that the chromatin fibers maintain efficient distant EPC . Here we investigate the roles of linker histone H1 and HMGN5 protein in EPC. A considerable negative effect of histone H1 on EPC depending on its C- and N-tails was shown. Protein HMGN5 that affects chromatin compaction and is associated with active chromatin counteracts EPC inhibition by H1. The data suggest that the efficiency of the interaction between the enhancer and the promoter depends on the structure and dynamics of the chromatin fiber localized between them and can be regulated by proteins associated with chromatin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934096 | PMC |
| http://dx.doi.org/10.1134/S0026898419060132 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spatial and Temporal Expression of High-Mobility-Group Nucleosome-Binding (HMGN) Genes in Brain Areas Associated with Cognition in Individuals with Down Syndrome.
Genes (Basel)
December 2021
Health and Movement Research Group, Faculty of Health, Universidad Santiago de Cali, Cali 76001, Colombia.
DNA methylation and histone posttranslational modifications are epigenetics processes that contribute to neurophenotype of Down Syndrome (DS). Previous reports present strong evidence that nonhistone high-mobility-group N proteins (HMGN) are epigenetic regulators. They play important functions in various process to maintain homeostasis in the brain.
View Article and Find Full Text PDF[Opposite Effects of Histone H1 and HMGN5 Protein on Distant Interactions in Chromatin].
Mol Biol (Mosk)
January 2020
Cancer Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA, 19422 USA.
Transcriptional enhancers in the cell nuclei typically interact with the target promoters over long stretches of chromatin, but the mechanism of this communication remains unknown. Previously we have developed a defined system for quantitative analysis of the rate of distant enhancer-promoter communication (EPC) and have shown that the chromatin fibers maintain efficient distant EPC . Here we investigate the roles of linker histone H1 and HMGN5 protein in EPC.
View Article and Find Full Text PDFArticle Synopsis
- HMGN5 is a non-histone protein that binds to nucleosomes and is thought to be involved in mouse endometrial decidualization, though its specific function in human endometrial stromal cells (HESCs) is not fully understood.
- In experiments, HESCs treated with 8-br-cAMP and MPA showed a significant decrease in HMGN5 expression, and using siRNA to inhibit HMGN5 increased the expression of key decidual marker genes.
- The research indicates that lower levels of HMGN5 promote decidualization in HESCs and suggest it might regulate the microRNA miR-542-3p during this process.
Chromatin decompaction by the nucleosomal binding protein HMGN5 impairs nuclear sturdiness.
Nat Commun
January 2015
Protein Section, Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
In most metazoan nuclei, heterochromatin is located at the nuclear periphery in contact with the nuclear lamina, which provides mechanical stability to the nucleus. We show that in cultured cells, chromatin decompaction by the nucleosome binding protein HMGN5 decreases the sturdiness, elasticity and rigidity of the nucleus. Mice overexpressing HMGN5, either globally or only in the heart, are normal at birth but develop hypertrophic heart with large cardiomyoctyes, deformed nuclei and disrupted lamina and die of cardiac malfunction.
View Article and Find Full Text PDFExpression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.
Oncol Rep
March 2015
Department of Urology, Peking University First Hospital and The Institute of Urology, Peking University, Beijing 100034, P.R. China.
Prostate cancer is a leading cause of cancer-related death among men. Early diagnosis and treatment are successful against prostate cancer, yet the clinical treatment of advanced prostate cancer remains a challenge. Gemcitabine is used to treat a broad spectrum of solid tumors; however, the clinical response of prostate cancer patients to gemcitabine is limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!